U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H16N4O3.ClH
Molecular Weight 300.741
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ULODESINE HYDROCHLORIDE

SMILES

Cl.OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)C[C@@H]1O

InChI

InChIKey=CMKFYLGNPVHLJV-RJUBDTSPSA-N
InChI=1S/C12H16N4O3.ClH/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19;/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19);1H/t8-,9+;/m1./s1

HIDE SMILES / InChI
Ulodesine (BCX4208) is a new, orally active, highly potent inhibitor of purine nucleoside phosphorylase (PNP) for the treatment of hyperuricemia and gout. Inhibition of PNP reduces the substrates available for XO to form uric acid. The drug is currently under development for the management of hyperuricemia in chronic gout. Two Phase II clinical trials have shown promising results regarding urate-lowering effect in both as monotherapy and in combination with allopurinol. Ulodesine shows no interaction with CYP450 isoforms and has no hepatic metabolism; therefore, no drug interactions were expected. Following the successful outcome of the Phase IIb clinical trial, Phase III development of ulodesine is planned. One concern regarding the use of ulodesine is its impact on T cells. Lack of PNP is associated with immunodeficiency and autoimmune disorders.

Approval Year

PubMed

PubMed

TitleDatePubMed
Investigational drugs for hyperuricemia.
2015
Expert opinion on emerging urate-lowering therapies.
2018 Sep
Patents

Sample Use Guides

In the 12-week randomized controlled trial, in 82 gout patients, the response rates to 5, 10, 20 and 40 mg ulodesine (BCX4208) compared with allopurinol 300 mg were 45, 33, 39 and 49%, respectively
Route of Administration: Oral
Ulodesine is a novel and potent inhibitor of purine nucleoside phosphorylase (PNP) with an IC50 of 0.5 nM.
Name Type Language
ULODESINE HYDROCHLORIDE
Common Name English
4H-PYRROLO(3,2-D)PYRIMIDIN-4-ONE, 1,5-DIHYDRO-7-(((3R,4R)-3-HYDROXY-4-(HYDROXYMETHYL)-1-PYRROLIDINYL)METHYL)-, MONOHYDROCHLORIDE
Common Name English
BCX-4208 HCL
Code English
4H-PYRROLO(3,2-D)PYRIMIDIN-4-ONE, 3,5-DIHYDRO-7-(((3R,4R)-3-HYDROXY-4-(HYDROXYMETHYL)-1-PYRROLIDINYL)METHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
BCX-4208 HYDROCHLORIDE
Code English
Code System Code Type Description
EPA CompTox
DTXSID20210563
Created by admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
PRIMARY
DRUG BANK
DBSALT002180
Created by admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
PRIMARY
CAS
615580-53-5
Created by admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
PRIMARY
FDA UNII
O0JCK72YU4
Created by admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
PRIMARY
PUBCHEM
135565454
Created by admin on Fri Dec 15 15:40:50 GMT 2023 , Edited by admin on Fri Dec 15 15:40:50 GMT 2023
PRIMARY